title: Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
abstract: BACKGROUND
  Previously some groups demonstrated that CD44 variant 6 (CD44v6) is correlated with progression and metastasis of ovarian cancer. However, a number of other groups failed to find such an association. Moreover, epithelial ovarian cancer is known to easily metastasize to distinct sites such as the pelvic and abdominal cavities, but the potential association of CD44v6 expression with site-specific metastasis of ovarian cancer has not been explored. This study sought to evaluate the expression of CD44 standard (CD44s) and CD44v6 in primary, metastatic and recurrent epithelial ovarian cancer to explore the potential association of CD44s and CD44v6 with tumor progression and recurrence.
  
  
  METHODS
  Tumor specimens were procured from patients with advanced (FIGO III, G3) and recurrent ovarian serous adenocarcinoma. CD44s and CD44v6 expression in the tumor tissues was evaluated by real-time RT-PCR and Western blot. Moreover, serum soluble CD44s or CD44v6 concentrations of early stage (FIGO I, G1), advanced (FIGO III, G3) and recurrent ovarian serous adenocarcinoma patients were determined by enzyme-linked immunosorbent assays (ELISA). CD44v6 expression in a different set of tumor samples on an ovarian cancer tissue chip was evaluated by immunohistochemistry (IHC) and the correlation of CD44v6 expression with clinicopathologic features was analyzed. Finally, the effects of knockdown of CD44v6 in SKOV3 cells on cell adhesion, invasion and migration were assessed.
  
  
  RESULTS
  The expression of CD44v6, but not CD44s, is up-regulated in recurrent ovarian serous cancer compared to advanced primary tumor. CD44v6 expression is also preferentially increased in the tumor at the abdominal cavity metastasis site of advanced diseases. Consistently, serum soluble CD44v6 levels of recurrent ovarian cancer were higher than those of early stage and advanced primary diseases. The IHC data demonstrate that CD44v6 expression is correlated with clinicopathologic features and tumor progression. Lastly, knockdown of CD44v6 decreases the adhesion and migration but not invasion capacities of SKOV3 cells.
  
  
  CONCLUSIONS
  CD44v6 expression levels are associated with epithelial ovarian cancer progression, metastasis and relapse. Moreover, serum soluble CD44v6 may be used as a potential marker for identifying tumor relapse. Finally, CD44v6 may play a role in ovarian cancer metastasis by mediating tumor cell adhesion and migration.
authors.affiliation: Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China.
authors.forename: Jun
authors.initials: J
authors.lastname: Shi
authors.forename: Zhou
authors.initials: Z
authors.lastname: Zhou
authors.forename: Wen
authors.initials: W
authors.lastname: Di
authors.forename: Ningli
authors.initials: N
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism* / Q000556:secondary; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D002465:Cell Movement; D018450:Disease Progression; D005260:Female; D055785:Gene Knockdown Techniques; D006801:Humans; D018960:Hyaluronan Receptors / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; C112697:CD44v6 antigen; D018960:Hyaluronan Receptors
references.citation: Auris Nasus Larynx. 2004 Mar;31(1):35-41
references.pmid: 15041052
references.citation: Br J Cancer. 1995 Dec;72(6):1494-7
references.pmid: 8519665
references.citation: Breast Cancer Res Treat. 2011 Dec;130(3):1029-36
references.pmid: 21830016
references.citation: Clin Exp Metastasis. 1996 Sep;14(4):325-34
references.pmid: 8878406
references.citation: Cell. 1991 Apr 5;65(1):13-24
references.pmid: 1707342
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Int J Biol Markers. 2011 Jan-Mar;26(1):50-7
references.pmid: 21279958
references.citation: EMBO J. 1991 Feb;10(2):343-8
references.pmid: 1991450
references.citation: J Obstet Gynaecol Res. 2006 Aug;32(4):379-86
references.pmid: 16882263
references.citation: Immunology. 1993 Apr;78(4):547-54
references.pmid: 8495972
references.citation: Differentiation. 1993 Sep;54(2):85-98
references.pmid: 7694885
references.citation: J Pathol. 1999 Nov;189(3):326-37
references.pmid: 10547593
references.citation: Oncol Rep. 1999 Jan-Feb;6(1):97-101
references.pmid: 9864409
references.citation: Cancer Res. 1994 Jan 15;54(2):422-6
references.pmid: 7506122
references.citation: Anticancer Res. 1997 Sep-Oct;17(5A):3633-45
references.pmid: 9413216
references.citation: Mol Cancer Res. 2011 Dec;9(12):1573-86
references.pmid: 21970856
references.citation: Ann Hematol. 2011 May;90(5):493-508
references.pmid: 21258793
references.citation: J Exp Med. 1993 Feb 1;177(2):443-55
references.pmid: 8426113
references.citation: J Exp Med. 1990 Feb 1;171(2):477-88
references.pmid: 2406365
references.citation: Int J Cancer. 2009 May 1;124(9):2124-34
references.pmid: 19142869
references.citation: Histochemistry. 1994 Feb;101(2):79-89
references.pmid: 7520892
references.citation: Oncol Rep. 2009 Oct;22(4):745-55
references.pmid: 19724852
references.citation: J Invest Dermatol. 2009 Jun;129(6):1321-4
references.pmid: 19434087
references.citation: J Pediatr Surg. 1994 Aug;29(8):1040-3
references.pmid: 7525917
references.citation: Ultrastruct Pathol. 2012 May;36(3):145-52
references.pmid: 22559040
references.citation: Gynecol Oncol. 2004 Oct;95(1):23-31
references.pmid: 15385106
references.citation: Int J Mol Med. 2000 Nov;6(5):595-601
references.pmid: 11029531
references.citation: Nat Rev Cancer. 2010 Nov;10(11):803-8
references.pmid: 20944665
references.citation: Nat Rev Cancer. 2011 Apr;11(4):254-67
references.pmid: 21390059
references.citation: Int J Mol Sci. 2011 Jan 31;12(2):1009-29
references.pmid: 21541039
references.citation: Nat Rev Cancer. 2009 Jun;9(6):415-28
references.pmid: 19461667
references.citation: Nat Rev Cancer. 2011 Sep 23;11(10):719-25
references.pmid: 21941283
references.citation: Cancer Lett. 1977 Sep;3(3-4):203-8
references.pmid: 902256
references.citation: Mol Pathol. 1999 Aug;52(4):189-96
references.pmid: 10694938
references.citation: Zhonghua Fu Chan Ke Za Zhi. 2000 Apr;35(4):225-8
references.pmid: 11776166
references.citation: Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12160-4
references.pmid: 1465456
references.citation: Gynecol Oncol. 1999 Mar;72(3):360-6
references.pmid: 10053108
references.citation: Eur J Immunol. 1982 Aug;12(8):659-63
references.pmid: 7140811
references.citation: Zhonghua Nan Ke Xue. 2004 Jan;10(1):32-4, 38
references.pmid: 14979205
references.citation: Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):309-14
references.pmid: 11759056
references.citation: Zhonghua Zhong Liu Za Zhi. 2001 Jan;23(1):46-9
references.pmid: 11783069
references.citation: Eur J Immunol. 1986 Oct;16(10):1195-202
references.pmid: 2429846
references.citation: Arch Surg. 2012 Jan;147(1):18-24
references.pmid: 22250106
references.citation: J Clin Gastroenterol. 1996 Mar;22(2):107-10
references.pmid: 8742647